Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danielle Duffy

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
American Heart Journal|April 24, 2012
The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarctionDanielle Duffy, Dajuanicia N Holmes, Matthew T Roe, et al.
Pharmacotherapy|June 6, 2014
Novel treatments for familial hypercholesterolemia: pharmacogenetics at workJeffrey A Marbach, Jessica L McKeon, Joyce L Ross, et al.
American Heart Journal|November 9, 2016
Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or strokeMichael Valentino, Jad Al Danaf, Andrew Panakos, et al.
Journal of the American Heart Association|May 3, 2024
CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial InfarctionBronwyn A Kingwell, Danielle Duffy, Regina Clementi, et al.
Pharmacotherapy|April 16, 2014
Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemiaSony Tuteja, Danielle Duffy, Richard L Dunbar, et al.
Journal of Clinical Pharmacology|November 20, 2018
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux CapacityAndreas Gille, Danielle Duffy, Michael A Tortorici, et al.
Mutation Research|December 19, 2006
Chromosome aberrations in Chinese hamster and human cells: a comparison using compounds with various genotoxicity profilesCathy Hilliard, Rosina Hill, Michael Armstrong, et al.
British Journal of Clinical Pharmacology|November 20, 2020
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patientsBo Zheng, Danielle Duffy, Pierluigi Tricoci, et al.
Journal of the American Heart Association|April 12, 2022
Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux CapacityBronwyn A Kingwell, Stephen J Nicholls, Elena Velkoska, et al.
Practical Radiation Oncology|May 10, 2015
Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath holdHarriet B Eldredge-Hindy, Danielle Duffy, Kosj Yamoah, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
American Heart Journal|April 24, 2012
The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarctionDanielle Duffy, Dajuanicia N Holmes, Matthew T Roe, et al.
Pharmacotherapy|June 6, 2014
Novel treatments for familial hypercholesterolemia: pharmacogenetics at workJeffrey A Marbach, Jessica L McKeon, Joyce L Ross, et al.
American Heart Journal|November 9, 2016
Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or strokeMichael Valentino, Jad Al Danaf, Andrew Panakos, et al.
Journal of the American Heart Association|May 3, 2024
CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial InfarctionBronwyn A Kingwell, Danielle Duffy, Regina Clementi, et al.
Pharmacotherapy|April 16, 2014
Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemiaSony Tuteja, Danielle Duffy, Richard L Dunbar, et al.
Journal of Clinical Pharmacology|November 20, 2018
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux CapacityAndreas Gille, Danielle Duffy, Michael A Tortorici, et al.
Mutation Research|December 19, 2006
Chromosome aberrations in Chinese hamster and human cells: a comparison using compounds with various genotoxicity profilesCathy Hilliard, Rosina Hill, Michael Armstrong, et al.
British Journal of Clinical Pharmacology|November 20, 2020
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patientsBo Zheng, Danielle Duffy, Pierluigi Tricoci, et al.
Journal of the American Heart Association|April 12, 2022
Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux CapacityBronwyn A Kingwell, Stephen J Nicholls, Elena Velkoska, et al.
Practical Radiation Oncology|May 10, 2015
Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath holdHarriet B Eldredge-Hindy, Danielle Duffy, Kosj Yamoah, et al.
Pageof 5